|Brand name(s), other common name(s)||Revlimid®|
|How the drug is given||By mouth|
Lenalidomide is FDA approved
- In combination with dexamethasone to treat patients with newly diagnosed multiple myeloma.
- In combination with dexamethasone, to treat patients with myeloma who have received at least one prior therapy.
- To treat transfusion-dependent anemia in patients with a certain type of myelodysplastic syndrome (MDS) called 5q MDS. Patients with this type of MDS may have low red blood cell counts and require blood transfusions.
- To treat patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (Velcade®).
Side effects needing medical attention: Arm or leg swelling; black, tarry stools; bleeding gums; blood in urine or stools; chest pain; chills; cough; convulsions; decreased urine or painful or difficult urination; difficult or labored breathing, shortness of breath or wheezing; dry mouth; fever; increased thirst; irregular heartbeat; loss of appetite; lower back or side pain; mood changes; muscle pain or cramps; nausea or vomiting; numbness or tingling in hands, feet or lips; pale skin; pinhead-sized red spots on skin; sore throat; sores, ulcers or white spots on lips or in mouth; swollen glands; tightness in chest; unusual bleeding or bruising; unusual tiredness or weakness.